Protagenic Therapeutics, Inc.
PTIX- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001022899
In the last 90 days, Protagenic Therapeutics, Inc. insiders filed 7 open-market purchases and 0 sales; 2 institutions reported holding it in 13F filings for Q2 2026, worth $25.4K in total; no superinvestor holds it.
13F holders, Q1 2023
Institutional positions in Protagenic Therapeutics, Inc. as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 10
- −8 vs. Q4 2022
- Shares held
- 95.4K
- −57.4K (−37.6%) vs. Q4 2022Converted for a 1-for-4 split
- Total value
- $164.2K
- −$83.7K (−33.8%) vs. Q4 2022
- New holders
- 0
- 2 more added
- Sold out
- 8
- 4 more reduced
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PTIX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 2 | $25.4K |
| Q1 2026 | 4 | $44.4K |
| Q4 2025 | 12 | $150.9K |
| Q3 2025 | 11 | $344.4K |
| Q2 2025 | 11 | $258.1K |
| Q1 2025 | 9 | $65.9K |
| Q4 2024 | 9 | $75.0K |
| Q3 2024 | 11 | $104.3K |
| Q2 2024 | 11 | $145.7K |
| Q1 2024 | 11 | $205.6K |
| Q4 2023 | 10 | $106.8K |
| Q3 2023 | 9 | $179.5K |
| Q2 2023 | 10 | $198.4K |
| Q1 2023 | 10 | $164.2K |
| Q4 2022 | 18 | $247.9K |
| Q3 2022 | 17 | $342.0K |
| Q2 2022 | 16 | $435.0K |
| Q1 2022 | 17 | $548.0K |
| Q4 2021 | 19 | $1.32M |
| Q3 2021 | 19 | $1.81M |
| Q2 2021 | 13 | $683.0K |
| Q1 2021 | 1 | $0 |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding Protagenic Therapeutics, Inc.; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 32,951 | $57.0K | 0.00% | −26,126−44.2% | ReducedConverted for a 1-for-4 split |
| Geode Capital Management, LLC | 25,399 | $43.9K | 0.00% | −500−1.9% | ReducedConverted for a 1-for-4 split |
| FNY Investment Advisers, LLC | 18,750 | $32.0K | 0.04% | 00.0% | UnchangedConverted for a 1-for-4 split |
| State Street Corp | 13,812 | $23.9K | 0.00% | 00.0% | UnchangedConverted for a 1-for-4 split |
| Advisor Group Holdings, Inc. | 2,764 | $4.78K | 0.00% | 00.0% | UnchangedConverted for a 1-for-4 split |
| Tower Research Capital LLC (TRC) | 1,438 | $2.00K | 0.00% | −114−7.3% | ReducedConverted for a 1-for-4 split |
| UBS Group AG | 305 | $528 | 0.00% | −3,983−92.9% | ReducedConverted for a 1-for-4 split |
| Wells Fargo & Company | 23 | $40 | 0.00% | +1+2.2% | AddedConverted for a 1-for-4 split |
| Bank of America Corp | 1 | $2 | 0.00% | 00.0% | UnchangedConverted for a 1-for-4 split |
| Morgan Stanley | 1 | $2 | 0.00% | +1+300.0% | AddedConverted for a 1-for-4 split |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −5,871−100.0% | Sold outConverted for a 1-for-4 split |
| Northern Trust Corp | 0 | $0 | 0.00% | −5,621−100.0% | Sold outConverted for a 1-for-4 split |
| Warberg Asset Management LLC | 0 | $0 | 0.00% | −5,000−100.0% | Sold outConverted for a 1-for-4 split |
| Concorde Asset Management, LLC | 0 | $0 | 0.00% | −4,180−100.0% | Sold outConverted for a 1-for-4 split |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −3,494−100.0% | Sold outConverted for a 1-for-4 split |
| Virtu Financial LLC | 0 | $0 | 0.00% | −2,528−100.0% | Sold outConverted for a 1-for-4 split |
| Harbor Investment Advisory, LLC | 0 | $0 | 0.00% | −0−100.0% | Sold outConverted for a 1-for-4 split |
| CWM, LLC | 0 | $0 | 0.00% | −1−100.0% | Sold outConverted for a 1-for-4 split |